Category Specific RSS

ASX:IMU

Imugene Advances Cancer Fight with 57% Complete Response Rate in CAR-T Trial

Industry Opportunity: Addressing a Critical Unmet Need The fight against blood cancer is evolving, and Imugene Limited (ASX:IMU) is at…

12 months ago

Issues clinical trial update of its Phase 1 MAST trial

Clinical stage immuno-oncology company Imugene Limited (ASX:IMU) provided a clinical trial update of its Phase 1 MAST (Metastatic Advanced Solid…

1 year ago